AnaptysBio Inc
ANAB · NASDAQ
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
Market Data
Price
$56.07
+1.83 (+3.37%)
Market Cap$1.63B
P/E Ratio—
EPS$—
52W High$72.36
52W Low$11.40
Beta0.86
Data from Finnhub · Updated Jun 15, 2026